Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03VPM
|
|||
| Former ID |
DIB004272
|
|||
| Drug Name |
DPV-001
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | |
| Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 1 | [2], [3] | ||
| Company |
Ubivac
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Toll-like receptor (TLR) | Target Info | Modulator | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038474) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | UbiVac's DRibble, autophagosome-enriched vaccines: Applications for cancer and infectious disease. UbiVac. 2013. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.